Skip to content

Study · Randomized controlled trial · n = 34 · 2020

3 results

Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.

Sim IW, Borromeo GL, Tsao C, Hardiman R, Hofman MS, Papatziamos Hjelle C, Siddique M, Cook GJR, Seymour JF, Ebeling PR

Journal of clinical oncology : official journal of the American Society of Clinical Oncology2 Jul 2020Cited by 93 (Europe PMC)

PMID32614699 (opens in a new tab)DOI10.1200/jco.19.02192 (opens in a new tab)PepBankPUB-32614699
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In medication-related jaw osteonecrosis, 45.4% of lesions resolved with teriparatide versus 33.3% with placebo by 52 weeks.

    In plain wordsIn medication-related jaw bone damage, more lesions resolved with teriparatide than placebo by 52 weeks.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseMRONJ lesion resolution by 52 weeks
    Study

    n = 34

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg/day · subcutaneous · 8 weeksAs given in this study (human).

    Measurements

    Lesions resolved
    45.4%
    teriparatide by 52 weeks
    Lesions resolved
    33.3%
    placebo by 52 weeks
    Odds ratio as reported
    0.15 ratio
    teriparatide, lesion resolution
    Odds ratio as reported
    0.4 ratio
    placebo, lesion resolution

    Source sentences

    Summary
    Teriparatide was associated with a greater rate of resolution of MRONJ lesions (odds ratio [OR], 0.15 v 0.40; P = .013), and 45.4% of lesions resolved by 52 weeks compared with 33.3% in the placebo group.
    2 context sentences
    Summary · context
    In a double-blind, randomized, controlled trial, 34 participants with established MRONJ, with a total of 47 distinct MRONJ lesions, were allocated to either 8 weeks of subcutaneous teriparatide (20 µg/day) or placebo injections, in addition to calcium and vitamin D supplementation and standard clinical care.
    Summary · context
    Participants were observed for 12 months, with primary outcomes that included the clinical and radiologic resolution of MRONJ lesions.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In participants with medication-related jaw osteonecrosis, teriparatide reduced bony defects compared with placebo at week 52.

    In plain wordsIn people with medication-related jaw bone damage, teriparatide reduced bone defects compared with placebo at week 52.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseBony defects at week 52
    Study

    n = 34

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 µg/day · subcutaneous · 8 weeksAs given in this study (human).

    Measurements

    Odds ratio
    8.1 ratio
    bony defects at week 52

    Source sentences

    Summary
    Teriparatide was also associated with reduced bony defects at week 52 (OR, 8.1; P = .017).
    2 context sentences
    Summary · context
    In a double-blind, randomized, controlled trial, 34 participants with established MRONJ, with a total of 47 distinct MRONJ lesions, were allocated to either 8 weeks of subcutaneous teriparatide (20 µg/day) or placebo injections, in addition to calcium and vitamin D supplementation and standard clinical care.
    Summary · context
    Participants were observed for 12 months, with primary outcomes that included the clinical and radiologic resolution of MRONJ lesions.
  3. 03HumanRandomized controlled trialSafety outcome

    In participants with medication-related jaw osteonecrosis, adverse event incidence was balanced between teriparatide and placebo, with most events mild.

    In plain wordsIn people with medication-related jaw bone damage, adverse events were similar with teriparatide and placebo, and most were mild.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeAdverse event incidence
    Study

    n = 34

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    20 µg/day · subcutaneous · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    The incidence of adverse events was balanced between groups, including nausea, anorexia, and musculoskeletal pain, most of mild severity.
    2 context sentences
    Summary · context
    In a double-blind, randomized, controlled trial, 34 participants with established MRONJ, with a total of 47 distinct MRONJ lesions, were allocated to either 8 weeks of subcutaneous teriparatide (20 µg/day) or placebo injections, in addition to calcium and vitamin D supplementation and standard clinical care.
    Summary · context
    Participants were observed for 12 months, with primary outcomes that included the clinical and radiologic resolution of MRONJ lesions.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.